Diabetes, Vol 42, Issue 2 233-238, Copyright © 1993 by American Diabetes Association
Elevation of factor XIa-alpha 1-antitrypsin complex levels in NIDDM patients with diabetic nephropathy
T Murakami, Y Komiyama, H Egawa and K Murata
Department of Clinico-laboratory Medicine, Kansai Medical University, Osaka, Japan.
Excess activated FXIa in plasma indicates hypercoagulability in the early
contact phase. We have already developed methods for detecting the
hypercoagulable state in clinical samples by our ELISA for complexed FXIa
and alpha 1AT, which has been confirmed to be the predominant inhibitor of
FXIa. In diabetes, whether the activation of FXI is associated with the
development of vascular complications remains unknown, although various
hemostatic abnormalities have been described. We tested the complexed
FXIa-alpha 1AT level in 45 NIDDM patients, who were divided into three
groups according to the development of diabetic nephropathy, as assessed by
UAE. Normoalbuminuria was defined as UAE < 15 micrograms/min,
microalbuminuria as UAE in the range of 15-200 micrograms/min, and
albuminuria as UAE > 200 micrograms/min. In the patients as a whole,
FXIa-alpha 1AT and TAT levels were significantly increased compared with
these levels in age-matched control subjects (17.3 +/- 5.7 vs. 12.4 +/- 2.4
ng/ml and 2.67 +/- 1.23 vs. 1.93 +/- 0.45 ng/ml, respectively). No
significant difference was observed between FXIa-alpha 1AT levels in the
control subjects and in the normoalbuminuric group (13.0 +/- 2.1 ng/ml; n =
19). However, in the microalbuminuric (17.9 +/- 3.9 ng/ml; n = 16) and
albuminuric (24.1 +/- 5.4 ng/ml; n = 10) groups, FXIa-alpha 1AT levels were
significantly increased compared with those in the control and
normoalbuminuric group. The TAT level was not correlated with FXIa-alpha
1AT, and no significant differences in its levels were found among these
diabetic groups.(ABSTRACT TRUNCATED AT 250 WORDS)